SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ — Hongkong Winhealth Pharma Group (Winhealth
Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland
China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB),
bullous